AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Vivos Therapeutics, Inc. has reported positive outcomes from a 7-month pilot program, indicating the success of its provider-based marketing strategy for adult obstructive sleep apnea patients. The pilot showed that 79% opted for Vivos' oral appliance therapy, while 5% declined all treatment and 16% chose to consider CPAP. The company's new marketing model, promoting collaboration with dentists and sleep providers, has yielded favorable results, demonstrating patients' preference for Vivos' OSA treatments when fully informed about risks and available options.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet